mRNA vaccination in breast cancer: current progress and future direction

Xiao-Ting Jiang1, Qiang Liu2

  • 1Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou, 510120, China.

Insights

Messenger RNA (mRNA) vaccination shows promise for breast cancer immunotherapy by converting non-responsive tumors into responsive ones. Further research into vaccine design and combination therapies is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Messenger RNA (mRNA) vaccination is a successful strategy against COVID-19 and a promising area for cancer immunotherapy.
  • Breast cancer, a prevalent malignancy in women, has limited patient access to current immunotherapy benefits.
  • mRNA technology offers potential to enhance immunotherapy response rates in breast cancer by modulating the tumor microenvironment.

Purpose of the Study:

  • To review pre-clinical and clinical data on mRNA vaccination platforms for breast cancer.
  • To discuss strategies for optimizing mRNA vaccine design and delivery for breast cancer treatment.
  • To explore combination approaches of mRNA vaccines with other immunotherapies to improve treatment efficacy.

Main Methods:

  • Review of existing pre-clinical and clinical studies on mRNA vaccines for breast cancer.
  • Analysis of factors influencing in vivo mRNA vaccine function, including targets, structures, vectors, and delivery routes.
  • Exploration of synergistic effects by combining mRNA vaccination with other immunotherapeutic modalities.

Main Results:

  • mRNA vaccines demonstrate potential to transform "cold" breast tumors into immunologically "hot" ones, increasing treatment responsiveness.
  • Various mRNA vaccination platforms are under investigation for their efficacy in breast cancer models.
  • Considerations for effective vaccine design include target selection, mRNA structure optimization, and appropriate delivery systems.

Conclusions:

  • mRNA vaccination represents a significant advancement with the potential to overcome immunotherapy resistance in breast cancer.
  • Optimizing mRNA vaccine design and delivery is key to maximizing therapeutic benefits.
  • Combination strategies involving mRNA vaccines and other immunotherapies may significantly improve treatment outcomes for breast cancer patients.

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
452
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
90
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Nuclear Export of mRNA02:31

Nuclear Export of mRNA

Before mRNAs are exported to the cytoplasm, it is crucial to check each mRNA for structural and functional integrity. Eukaryotic cells use several different mechanisms, collectively known as mRNA surveillance, to look for irregularities in mRNAs. Irregular or aberrant mRNA are rapidly degraded by various enzymes. If a defective mRNA escapes the surveillance, it would be translated into a protein which would either be non-functional or not function properly. One of the primary irregularities in...
7.7K